Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's disease
- 74 Downloads
Arecoline, a cholinergic agonist, administered at low doses by continuous intravenous infusion for up to 2 weeks, significantly and replicably improved memory in five of nine subjects with mild-moderate Alzheimer's disease. During dose finding, performance on a verbal memory task improved with an inverted U-shaped relation to dose. Six of nine subjects were classified as responders. During blinded, placebo-controlled, individualized optimal dosing for 5 days, verbal memory again improved in five of six responders but not in any non-responder. No adverse drug effects occurred. Arecoline, and possibly other cholinergic agonists, can safely improve memory in Alzheimer's disease at doses much lower than previously studied.
Key wordsArecoline Alzheimer's disease Memory
Unable to display preview. Download preview PDF.
- Benton AL (1974) Revised visual retention test manual. Psychological, New YorkGoogle Scholar
- Berardi A, Haxby JV, Grady CL, Rapoport SI (1991) Asymmetries of brain glucose metabolism and memory in healthy aging. Dev Neuropsychol 7:87–97Google Scholar
- Caine E (1980) Cholinomimetic treatment fails to improve memory disorders. N Engl J Med 303:585Google Scholar
- Gauthier S, Bouchard R, Lamontagne A, Bailey P, Bergman H, Ratner J, Tesfaye Y, Saint-Martin M, Bacher Y, Carrier L (1990) Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study. New Engl J Med 322:1272–1276PubMedGoogle Scholar
- Golden CJ (1978) The Stroop color and word test: a manual for clinical and experimental uses. Stoelting, ChicagoGoogle Scholar
- Gotestam KG (1981) A geriatric rating scale empirically derived from three rating scales for geriatric behaviour. Acta Psychiat Scand Suppl 294:54–63Google Scholar
- Mash DC, Flynn DD, Potter LT (1985) Loss of M2 muscarinic receptors in the cerebral cortex in Alzheimer's disease and extrapyramidal cholinergic denervation. Science 228:1115–1117Google Scholar
- Wechsler DA (1955) Wechsler Adult Intelligence Scale. Psychological, New YorkGoogle Scholar
- Wettstein A, Spiegel R (1984) Clinical trials with the cholinergic drug RS 86 in Alzheimer's disease and senile dementia of the Alzheimer type. Psychopharmacology 84:572–573Google Scholar